{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:30:21Z","timestamp":1793320221590,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>We aim to evaluate the clinical pharmacokinetics of a single dose interleukin\u20106 (IL\u20106) antibody tocilizumab (TCZ) in methylprednisolone (MP)\u2010treated COVID\u201019 patients with cytokine storm syndrome (CSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MP pre\u2010treated patients with COVID\u201019\u2010associated CSS, defined as at least two elevations of C\u2010reactive protein (CRP) &gt;100\u2009mg\/L, ferritin &gt;900\u2009\u03bcg\/L or D\u2010dimers &gt;1500\u2009\u03bcg\/L, received intravenous TCZ (8\u00a0mg\/kg, max. 800\u2009mg) upon clinical deterioration. A nonlinear\u2010mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration\u2013time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID\u201019 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1\u00a0\u03bcg\/L target saturation threshold were covered for 16\u2009days in all evaluated patients treated with a single dose of 8\u00a0mg\/kg. In a simulation with TCZ 400\u2009mg fixed dose, this condition of full IL\u20106 receptor occupancy at minimum serum concentration was also met.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A single dose (8\u00a0mg\/kg, max. 800\u2009mg) is sufficient to cover a period of 16\u2009days of IL\u20106\u2010mediated hyperinflammation in COVID\u201019\u2010induced CSS in MP\u2010treated patients. Based on body weight PK simulations, a fixed\u2010dose tocilizumab of 400\u2009mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15690","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T23:53:32Z","timestamp":1676505212000},"page":"938-946","source":"Crossref","is-referenced-by-count":4,"title":["Single dose tocilizumab for COVID\u201019 associated cytokine storm syndrome: Less is more"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-2726","authenticated-orcid":false,"given":"Niels W.","family":"Boone","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacology and Toxicology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Centre  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Zuyderland Medical Centre  Heerlen The Netherlands"},{"name":"Department of Rheumatology Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy L. M.","family":"Mostard","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Zuyderland Medical Centre  Heerlen The Netherlands"},{"name":"Department of Respiratory Medicine Maastricht University Medical Centre  Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Magro\u2010Checa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel M. P.","family":"van Dongen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Gronenschild","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"van Haren","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Buijs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"de Vries","sequence":"additional","affiliation":[{"name":"Biologics Lab Sanquin Diagnostic Services  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B. M.","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Zuyderland Medical Centre  Heerlen The Netherlands"},{"name":"Amsterdam Rheumatology &amp; Immunology Centre  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacology and Toxicology Zuyderland Medical Centre  Heerlen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30628\u20100"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010218479"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201005\u2010155846"},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency.SmPC tocilizumab. Amsterdam: European Medicines Agency;2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_nl.pdf. Updated October 25 2022; accessed November 11 2022."},{"key":"e_1_2_10_9_1","volume-title":"FDA multi\u2010discipline review tocilizumab cytokine release syndrome","author":"US FDA","year":"2017"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103045"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.07.21249390"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11330"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010021\u201001074\u20102"},{"key":"e_1_2_10_15_1","volume-title":"NONMEM User's Guides (1989\u20132006)","author":"Beal S","year":"2006"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010019\u201000765\u20101"},{"key":"e_1_2_10_20_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2013"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"e_1_2_10_22_1","unstructured":"Zorg Instituut Nederland.Medicijnkosten roactemra [internet]. Diemen Netherlands: ZIN;2022.https:\/\/www.medicijnkosten.nl\/medicijn?artikel=ROACTEMRA+INFVLST+CONC+20MG%2FML+FLACON+10ML&id=6dd8402bbebbc2d74d02b2fb937a5d35. Updated October 1 2022; accessed November 11 2022."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010020\u201001060\u20105"},{"key":"e_1_2_10_24_1","unstructured":"European Medicines Agency.DHPC Roactemra. Amsterdam: European Medicines Agency;2021.https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/roactemra-tocilizumab-temporary-supply-shortage. Updated September 3 2021; accessed July 26 2022."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11030258"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1812437"},{"key":"e_1_2_10_27_1","first-page":"ofab608","volume-title":"Open Forum Infectious Diseases","author":"Kumar PN","year":"2021"},{"key":"e_1_2_10_28_1","unstructured":"European Medicines Agency.Assessment report Roactemra. Amsterdam: European Medicines Agency;2021[updated 2021 December 21; cited 2023 January 24]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/roactemra-h-c-955-ii-0101-epar-assessment-report-variation_en.pdf. Updated December 21 2021; accessed January 24 2023."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:44:12Z","timestamp":1744451052000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bcp.15690"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15690","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}